Introducing new domains of research governance; Govind C. Persad, JD, BS, BA -- Should Research Ethics Encourage the Production of Cost-Effect Interventions?; Rebecca Johnson, MA -- From altruists to Workers: What Claims Should Healthy Participants in Phase I Trials Have Against Trial Employers?; Luana Colloca, PhD -- Nocebo effect: The dilemma of disclosing adverse events; Jan-Ole Reichardt, MA -- Encouraging conscientiousness in risk associated areas of medical research Challenges in common domains of research governance; Sara Anna Suzan Dekking, MAE et al -- Discriminating between Research and Care in Paediatric Oncology. Ethical Appraisal of the ALL- 10 and 11 protocols of the Dutch Childhood Oncology Group (DCOG); Imme Petersen, PhD et al -- What Does the Child's Assent to Research Participation Mean to Parents? Empirical Findings in Paediatric Oncology in Germany; Marcin Waligóra, PhD -- Assent in paediatric research and its consequences; Rosemarie Bernabe, PhD -- Ethical Issues in Postauthorization Drug Trials; Anette Blümle, PhD et al -- Fate of Clinical Research Studies after Ethical Approval - Follow-Up of Study Protocols until Publication; Daniel Strech, MD, PhD -- et al. Do editorial policies support ethical research? A thematic text analysis of author instructions in psychiatry journals Improving common domains of research governance; Jonathan Kimmelman, PhD -- Risk/Benefit Assessment in Launching Early Human Trials; Annette Rid, MD -- Guidelines for Biomedical Research Involving Human Subjects Setting Thresholds of Acceptable Research Risk: Lessons from the Debate about Minimal Risk; Sapfo Lignou, MSc, MA et al -- Towards an Alternative Account for Defining Acceptable Risk in Non-beneficial Pediatric Research; Roger Brownsword, PhD -- Big biobanks: Three Major Governance Challenges and Some Mini-Constitutional Responses; Bettina Schmietow, MA -- Dynamic Consent to Biobank Research - Paradigm Shift or Red Herring?.